Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling

Antioxidants and Redox Signaling

Volumn 20, Issue 12, 2014, Pages 1866-1880

  Du, Yanzhi ^a   Xia, Yuan ^a,b   Pan, Xiaoling ^a,b   Chen, Zi ^c   Wang, Aihua ^d   Wang, Kankan ^d   Li, Junmin ^d   Zhang, Ji ^a,d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; FENRETINIDE; IMATINIB; KI 67 ANTIGEN; TRANSCRIPTOME; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL SUBPOPULATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; CONTROLLED STUDY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ERYTHROID CELL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPOTENT STEM CELL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VERY ELDERLY; YOUNG ADULT; DRUG EFFECTS; IMMUNOLOGY; K562 CELL LINE; METABOLISM; PATHOLOGY;

ANTIGENS, CD34; BENZAMIDES; FENRETINIDE; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; OXIDATION-REDUCTION; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84886508283     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4935     Document Type: Article

References (60)

1. Gene Ontology Consortium. The Gene Ontology project in 2008. Nucleic Acids Res 36: D440-D444, 2008
2. Andrews NC. The NF-E2 transcription factor. Int J Biochem Cell Biol 30: 429-432, 1998
3. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, and Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701-4707, 2003
4. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, and Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999
5. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, and Holyoake TL. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107: 4532-4539, 2006
6. Corazzari M, Lovat PE, Armstrong JL, Fimia GM, Hill DS, Birch-Machin M, Redfern CP, and Piacentini M. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: The role of stress proteins ERdj5 and ERp57. Br J Cancer 96: 1062-1071, 2007
7. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, and Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121: 396-409, 2011
8. Cortes J, O'Brien S, and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204-2205, 2004
9. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, and Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64: 672-677, 2004
10. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, and Larson RA. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, and Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996
12. Du Y, Wang K, Fang H, Li J, Xiao D, Zheng P, Chen Y, Fan H, Pan X, Zhao C, Zhang Q, Imbeaud S, Graudens E, Eveno E, Auffray C, Chen S, Chen Z, and Zhang J. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 107: 1582-1590, 2006
13. Fang H, Yang Y, Li C, Fu S, Yang Z, Jin G, Wang K, Zhang J, and Jin Y. Transcriptome analysis of early organogenesis in human embryos. Dev Cell 19: 174-184, 2010
14. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B, Bellani FF, and Formelli F. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039, 2003
15. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, and Zhang J. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5: R80, 2004
16. Ghaffari S. Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxid Redox Signal 10: 1923-1940, 2008
17. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, and Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325, 2002
18. Hail N Jr., Kim HJ, and Lotan R. Mechanisms of fenretinideinduced apoptosis. Apoptosis 11: 1677-1694, 2006
19. Helgason GV, Young GA, and Holyoake TL. Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep 5: 81-87, 2010
20. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, and Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99: 3792-3800, 2002
21. Holyoake T, Jiang X, Eaves C, and Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94: 2056-2064, 1999
22. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, and Radich JP. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349: 1423-1432, 2003
23. Jaiswal AK. Jun and Fos regulation of NAD(P)H: Quinone oxidoreductase gene expression. Pharmacogenetics 4: 1-10, 1994
24. Jiang L, Pan X, Chen Y, Wang K, Du Y, and Zhang J. Preferential involvement of both ROS and ceramide in fenretinideinduced apoptosis of HL60 rather than NB4 and U937 cells. Biochem Biophys Res Commun 405: 314-318, 2011
25. Johnsen O, Skammelsrud N, Luna L, Nishizawa M, Prydz H, and Kolsto AB. Small Maf proteins interact with the human transcription factor TCF11/Nrf1/LCR-F1. Nucleic Acids Res 24: 4289-4297, 1996
26. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, and Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells. Blood 109: 4016-4019, 2007
27. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, and Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomepositive chronic phase chronic myeloid leukemia. Blood 103: 2873-2878, 2004
28. Kedi X, Ming Y, Yongping W, Yi Y, and Xiaoxiang Z. Free cholesterol overloading induced smooth muscle cells death and activated both ER-And mitochondrial-dependent death pathway. Atherosclerosis 207: 123-130, 2009
29. Lee TL, Shyu YC, Hsu PH, Chang CW, Wen SC, Hsiao WY, Tsai MD, and Shen CK. JNK-mediated turnover and stabilization of the transcription factor p45/NF-E2 during differentiation of murine erythroleukemia cells. Proc Natl Acad Sci USA 107: 52-57, 2010
30. Li YJ, Higgins RR, Pak BJ, Shivdasani RA, Ney PA, Archer M, and Ben-David Y. p45(NFE2) is a negative regulator of erythroid proliferation which contributes to the progression of Friend virus-induced erythroleukemias. Mol Cell Biol 21: 73-80, 2001
31. Lovat PE, Ranalli M, Bernassola F, Tilby M, Malcolm AJ, Pearson AD, Piacentini M, Melino G, and Redfern CP. Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents. Med Pediatr Oncol 35: 663-668, 2000
32. Malone W, Perloff M, Crowell J, Sigman C, and Higley H. Fenretinide: A prototype cancer prevention drug. Expert Opin Investig Drugs 12: 1829-1842, 2003
33. Maurer BJ, Melton L, Billups C, Cabot MC, and Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92: 1897-1909, 2000
34. Mi H, Guo N, Kejariwal A, and Thomas PD. PANTHER version 6: Protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 35: D247-D252, 2007
35. Miller W, Rosenbloom K, Hardison RC, Hou M, Taylor J, Raney B, Burhans R, King DC, Baertsch R, Blankenberg D, Kosakovsky Pond SL, Nekrutenko A, Giardine B, Harris RS, Tyekucheva S, Diekhans M, Pringle TH, Murphy WJ, Lesk A, Weinstock GM, Lindblad-Toh K, Gibbs RA, Lander ES, Siepel A, Haussler D, and Kent WJ. 28-way vertebrate alignment and conservation track in the UCSC Genome Browser. Genome Res 17: 1797-1808, 2007
36. Moon RC, McCormick DL, Becci PJ, Shealy YF, Frickel F, Paust J, and Sporn MB. Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis 3: 1469-1472, 1982
37. Naka K, Muraguchi T, Hoshii T, and Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal 10: 1883-1894, 2008
38. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, and Skorski T. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 119: 4253-4263, 2012
39. Ogasawara MA and Zhang H. Redox regulation and its emerging roles in stem cells and stem-like cancer cells. Antioxid Redox Signal 11: 1107-1122, 2009
40. Ohshima M, Ward JM, and Wenk ML. Preventive and enhancing effects of retinoids on the development of naturally occurring tumors of skin, prostate gland, and endocrine pancreas in aged male ACI/segHapBR rats. J Natl Cancer Inst 74: 517-524, 1985
41. Ohtsuji M, Katsuoka F, Kobayashi A, Aburatani H, Hayes JD, and Yamamoto M. Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J Biol Chem 283: 33554-33562, 2008
42. Ono Y, Wang Y, Suzuki H, Okamoto S, Ikeda Y, Murata M, Poncz M, and Matsubara Y. Induction of functional platelets from mouse and human fibroblasts by p45NF-E2/Maf. Blood 120: 3812-3821, 2012
43. Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, and Deshaies RJ. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell 38: 17-28, 2010
44. Rodrigues MS, Reddy MM, and Sattler M. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: From molecular redox mechanisms to health implications. Antioxid Redox Signal 10: 1813-1848, 2008
45. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, and Mahon FX. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109: 58-60, 2007
46. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293, 1973
47. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, and Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99: 3530-3539, 2002
48. Shan D, Gopal AK, and Press OW. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Clin Cancer Res 7: 2490-2495, 2001
49. Shaulian E and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136, 2002
50. Shen HM and Liu ZG. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 40: 928-939, 2006
51. Shtivelman E, Lifshitz B, Gale RP, and Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315: 550-554, 1985
52. Sun SY, Li W, Yue P, Lippman SM, Hong WK, and Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 59: 2493-2498, 1999
53. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, and Sawyers CL. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99: 1928-1937, 2002
54. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, DePinho RA, and Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128: 325-339, 2007
55. Usuki K, Iijima K, Iki S, and Urabe A. CML cytogenetic relapse after cessation of imatinib therapy. Leuk Res 29: 237-238, 2005
56. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, and Sporn MB. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847-1856, 1999
57. Wang K, Fang H, Xiao D, Zhu X, He M, Pan X, Shi J, Zhang H, Jia X, Du Y, and Zhang J. Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells. PLoS One 4: E7538, 2009
58. Zhang H, Mi JQ, Fang H, Wang Z, Wang C, Wu L, Zhang B, Minden M, Yang WT, Wang HW, Li JM, Xi XD, Chen SJ, Zhang J, Chen Z, and Wang KK. Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci USA 110: 5606-5611, 2013
59. Zhang Y, Du Y, Le W, Wang K, Kieffer N, and Zhang J. Redox control of the survival of healthy and diseased cells. Antioxid Redox Signal 15: 2867-2908, 2011
60. Zong Y, Zhou S, and Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia 19: 1590-1596, 2005.